(c) a mixture of hydrophilic and lipophilic solvents is from about 80:20 to about 5:95;

wherein said composition is effective to form said film coated liquid implant at said implant site [a film encapsulated liquid *in situ*].

Claim 2. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein said bioactive substance is present in about 1 to 10% w/v.

Claim 3. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein said poly(lactide-co-glycolide) copolymer is present in about 1 to 10% w/v.

Claim 4. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein the ratio of said hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 5. (Amended Twice) The film coated liquid implant [composition] of Claim 1 [which comprises] formed by injecting a composition comprising:

(a) 1 to 10% w/v of a hydrophobic bioactive substance;

(b) 1 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and

(c) a mixture of hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 6. (Amended Twice) The film coated liquid implant [composition] of Claim 1 [which comprises] formed by injecting a composition comprising:

(a) 5 to 10% w/v of a hydrophobic bioactive substance;

(b) 5 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and

(c) a mixture of hydrophilic and lipophilic solvents is from about 65:35 to about 35:65.

Claim 7. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein said bioactive substance is selected from fipronil, the avermectins, ivermectins, eprinomectin, milbemycins, nodulisporic acid and derivatives thereof, estradiol benzoate, trenbolone acetate, progesterone, and norethisterone.

Claim 8. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 95:5 to about 50:50.

Claim 9. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35.

Claim 10. (Amended Twice) The film coated liquid implant [composition] of Claim 1 wherein said hydrophilic solvent is selected from glycerol formal, glycofural, N-methyl pyrrolidone, 2-pyrrolidone, isopropylidene glycerol, di(propylene glycol) methyl ether, and mixtures thereof.

Claim 11. (Amended Twice) The film coated liquid implant [composition] of Claim 1 [which comprises] formed by injecting a composition comprising:

(a) 5 to 10% w/v of a hydrophobic bioactive substance;

(b) 5 to 10% w/v of a poly(lactide-co-glycolide) copolymer; wherein the ratio of lactide:glycolide of the poly(lactide-co-glycolide) copolymer is from about 75:25 to about 65:35, and the weight ratio of the poly(lactide-co-glycolide) copolymer to the hydrophobic bioactive substance is 1:1 or less; and

(c) a mixture of glycerol formal and triacetin wherein the volume ratio of glycerol formal and triacetin is from about 65:35 to about 35:65.

Claim 12. (Amended) A method for the controlled release of a hydrophobic bioactive substance in an animal, including human, which comprises injecting said animal with a liquid polymeric composition to form the film coated liquid implant of Claim 1.

Claim 13. (Amended Twice) A film coated liquid implant formed by a method comprising:

injecting into a subject in need of said implant at an implant site a liquid polymeric composition comprising:

(a) about 1-30% w/v of at least one bioactive substance;

(b) about 1-20% w/v of at least one biologically acceptable polymer, wherein the weight ratio of the polymer to the bioactive substance is 1:1 or less; and

(c) at least one lipophilic solvent or a mixture of at least one hydrophilic solvent and at lest one lipophilic solvent, wherein the volume ratio of the hydrophilic and lipophilic solvents is from about 80:20 to about 0:100, and/or wherein the lipophilic solvent is present in an amount of at least about 16.5% by weight;

wherein said composition is effective to form a film coated [encapsulated] liquid at said implant site [*in situ*].

Claim 14. (Amended) A method for the controlled release of a hydrophobic bioactive substance in an animal, including human, which comprises injecting said animal with a liquid polymeric composition to form the film coated liquid implant of Claim 13.

Remarks

The claims are 1-14. Claims 1-14 have been amended to claim a product-by-process, specifically the film coated liquid implant formed by injecting the compositions into a subject in need of such implant. Support for this recitation can be found in the original specification at, for example, page 9, lines 21-30. Accordingly, the changes are not new matter.

I. Rejections under 35 U.S.C. §112

Claims 1-14 have been rejected as allegedly being unclear as to the meaning of *in situ*. The term has been changed to "at said implant site" to clearly describe the present liquid polymeric composition forming a film coated liquid implant at the implant site after injection to the implant site.

Accordingly, applicants respectfully submit that the rejections under 35 U.S.C. §112 have been overcome and request withdrawal of the rejections.